The company’s CEO, Anders Månsson, announced in July his wish to leave his position with the company no later than after the 3-month stipulated notice period.
“I wish Anders Månsson all the best in his new endeavours and sincerely thank him for his period as CEO of RhoVac. Anders did an excellent job, not least regarding the company’s communication, both in success and adversity. We had a well-prepared exit process that could have been executed if only the crucial study, BRaVac, had reached its primary objective,” says Gunnar Gårdemyr, Chairman of the Board.
Anders Månsson will leave RhoVac no later than September 30. Board member Lars Hedbys took over as acting CEO of RhoVac on 1 September
A possible merger
Furthermore, the Board has not ruled out a possible merger with another company, in which case such a company will need to be headed by another CEO.
An Extraordinary General Meeting will be convened shortly to decide on the alternatives available to the company given the situation that has arisen after the negative primary results of BRaVac.